Drug Discovery World

APRIL 8, 2024

Following this, Benjamin Cravatt, Professor and the Norton Gilula Chair in Biology and Chemistry at The Scripps Research Institute, discussed activity-based protein profiling (ABPP) and its use in discovering drug candidates for cancer-relevant proteins.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Drug Discovery World

JANUARY 23, 2023

Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance. Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

Drug Discovery World

OCTOBER 27, 2023

With cues from a diverse population of tissue-specific cell types, extracellular matrix proteins, and biomechanical forces, cells grown in organ-chips closely emulate their in vivo counterparts and replicate tissue-level functions. But can organ-chips entirely replace other models? Not yet, according to Ewart.

Research 72

Research Gene Therapy In-Vivo In-Vitro 72

Drug Discovery World

APRIL 3, 2023

As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

AUGUST 3, 2022

Over the years, a range of different CPPs have been developed, including natural translocating proteins through to newly-designed computer-prediction sequences 3. Currently, only a small number of CPP-based oligonucleotide delivery examples have been reported for in vivo application. How are cell-penetrating peptides used?

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

Drug Discovery World

JULY 22, 2022

By Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences. Patient-derived xenografts (PDX) of melanoma were grafted into hIL2 mice, and TILs derived from the same melanoma patient were reactivated and expanded in vitro with IL2 and used to treat the PDX engrafted in the mice. Jespersen et al.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

Pharmaceutical Technology

JANUARY 4, 2023

Findings from a study, which was conducted by Transcenta and Shanghai Jiao Tong University scientists on TST003 to treat androgen receptor-negative/low prostate cancer, were published by Nature Cancer in May last year. The Gremlin1 protein was found to promote lineage plasticity while driving castration resistance in prostate cancer.

Antibody 242

Antibody In-Vivo In-Vitro Protein 242